Does cancer fear chemotherapy? Surgery? Radiation? These therapies, what I disaﬀectionately call the ‘unholy trinity’, can damage, debulk, and destroy tumors, but they do not create lasting immune memory.

In fact, research highlights numerous mechanisms by which they promote metastasis (epithelial-mesenchymal transition, increased circulating tumor cells, formation of tumor microenvironments of metastasis, lymph/angiogenesis, myeloid cell recruitment and reprogramming, tumor immune environment reprogramming, formations of pre-metastatic niches, extracellular vesicles (exosomes), metastatic signaling, endothelial barrier disruption, increased vascular permeabillity, cancer stem cell enrichment, immunosuppression, neutrophil extracellular traps, platelete activation, stromal remodeling, hypoixa and HIF-1α Activation, cytokine storm, and sympathetic nervous system activation ; almost all proposed mechanisms involve immune disruption.

Remember, 90% of morbidity and mortality occur when cancer spreads—metastasizes.

Cancer fears an engaged, activated, and competent immune system.

This insight came into focus for me through a recent study on Ewingella americana, a bacterium isolated from the intestines of Japanese tree frogs. While social media headlines focused on tumor destruction in mice, the more compelling aspect is what occurred within the tumor microenvironment.

After intravenous delivery in five mice, the bacterium preferentially localized to the hypoxic tumor regions—the very areas where cancer evolves, adapts, and hides from the immune system.

Hypoxia marks the forefront of cancer progression, driving immune exclusion, immune desert, abnormal vasculature, TGF-β signaling, and suppressive immune cell accumulation. All of these factors culminate in immune evasion.

However, once within these hypoxic zones, E. americana actively transformed the environment from immune silence to immune activation.

The reported findings went beyond simple tumor cell death. To focus only on cell death would be to miss the broader implications.

The study found increased infiltration of T cells, B cells, and neutrophils within the tumor, elevated TNF-α and IFN-γ levels, and durable, systemic immune memory—with complete rejection of tumor rechallenge in the five previously cured mice.

These data suggest a narrative less about a bacterium killing cancer, and more about a bacterium awakening the immune system.

Thus, it becomes clear: the tumor fears the immune system.

This raises the question: how does this approach compare with chemotherapy or conventional immune checkpoint-inhibiting immunotherapy?

Two additional study arms addressed the impact of conventional cancer treatment. Each included five mice: one group received liposomal doxorubicin (chemotherapy), and the other received anti-PD-L1 therapy (immunotherapy).

Notably, the E. americana arm outperformed both.

In other words, immune system engagement and activation surpassed both chemotherapy and immunotherapy.

Finally, consider how this sequence—tumor localization, danger signaling, innate immune recruitment, enhanced antigen presentation, adaptive immune expansion, and immune memory—closely mirrors the objectives underlying current intratumoral immunotherapystrategies.

Although this study is preliminary, with data from only five mice per group and no human results, it highlights a principle that has been demonstrated across nearly 150 years of research, from Coley’s toxins and BCG to today’s therapies: the immune system is pivotal in cancer therapy.

It is not the bacterium that cancer fears, but the immune response triggered by E. americana.

This little bacterium triggered:

IMMUNE LOCALIZATION → INFILTRATION → ACTIVATION → RECRUITMENT → ENHANCEMENT → EXPANSION → and INDUCTION OF SYSTEMIC MEMORY.

Learn what cancer approach is best for you by completing the Cancer Wellness Navigator self-inquiry here.

References:

Iwata S, Yamashita N, Asukabe K, Sakari M, Miyako E. Discovery and characterization of antitumor gut microbiota from amphibians and reptiles: Ewingella americana as a novel therapeutic agent with dual cytotoxic and immunomodulatory properties. Gut Microbes. 2025;17(1):2599562.
Alix-Panabières, C., & Pantel, K. (2014). Challenges in circulating tumour cell research. Nature Reviews Cancer, 14(9), 623–631. https://doi.org/10.1038/nrc3820
Coﬀelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016). Neutrophils in cancer: Neutral no more. Nature Reviews Cancer, 16(7), 431–446. https://doi.org/10.1038/nrc.2016.52
Daenen, L. G. M., Roodhart, J. M. L., van Amersfoort, M., Dehnad, M., Roessingh, W., Ulfman, L. H., Derksen, P. W. B., & Voest, E. E. (2011). Chemotherapy enhances metastasis formation via VEGFR-1–expressing endothelial cells. Cancer Research, 71(22), 6976–6985. https://doi.org/10.1158/0008-5472.CAN-11-0627
Guan, X., Ma, F., Sun, X., Li, C., Li, L., Liang, F., Li, S., Yi, Z., Liu, B., & Xu, B. (2020). Gut microbiota profiling in patients with HER2-negative metastatic breast cancer receiving metronomic chemotherapy of capecitabine compared to those under conventional dosage. Frontiers in Oncology, 10, 902. https://doi.org/10.3389/fonc.2020.00902
Karagiannis, G. S., Pastoriza, J. M., Wang, Y., Harney, A. S., Entenberg, D., Pignatelli, J., Sharma, V. P., Xue, E. A., Cheng, E., D’Alfonso, T. M., Jones, J. G., Anampa, J., Rohan, T. E., Sparano, J. A., Condeelis, J. S., & Oktay, M. H. (2017). Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Science Translational Medicine, 9(397), eaan0026. https://doi.org/10.1126/scitranslmed.aan0026
Karagiannis, G. S., Condeelis, J. S., & Oktay, M. H. (2019). Chemotherapy-induced metastasis: Molecular mechanisms, clinical manifestations, therapeutic interventions. Cancer Research, 79(18), 4567–4576. https://doi.org/10.1158/0008-5472.CAN-19-0646
Liu, Y., & Cao, X. (2016). Immunosuppressive cells in tumor immune escape and metastasis. Journal of Molecular Medicine, 94(5), 509–522. https://doi.org/10.1007/s00109-015-1376-x
Oskarsson, T., Batlle, E., & Massagué, J. (2014). Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell, 14(3), 306–321. https://doi.org/10.1016/j.stem.2014.02.002
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., Bissell, M. J., Cox, T. R., Giaccia, A. J., Erler, J. T., Hiratsuka, S., Ghajar, C. M., & Lyden, D. (2017). Pre-metastatic niches: Organ-specific homes for metastases. Nature Reviews Cancer, 17(5), 302–317. https://doi.org/10.1038/nrc.2017.6
Perelmuter, V. M., Dvornichenko, V. V., & Denisov, E. V. (2019). Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in breast cancer. Molecular Biology Reports, 46(3), 3537–3545.
Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423–1437. https://doi.org/10.1038/nm.3394
Sceneay, J., Smyth, M. J., & Möller, A. (2013). The pre-metastatic niche: Finding common ground. Cancer and Metastasis Reviews, 32(3–4), 449–464. https://doi.org/10.1007/s10555-013-9420-1
Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., & Kroemer, G. (2021). Intestinal microbiota influences clinical outcome and side eﬀects of early breast cancer treatment. Cell Death & Diﬀerentiation, 28(9), 2778–2796. https://doi.org/10.1038/s41418-021-00784-1
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., … Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune eﬀects of cyclophosphamide. Science, 342(6161), 971–976. https://doi.org/10.1126/science.1240537
Wu, A. H., Tseng, C.-H., Vigen, C., Yu, Y., Cozen, W., Garcia, A. A., Hawes, D., Spicer, D., & Wang-Rodriguez, J. (2022). Eﬀect of chemotherapy on the gut microbiome of breast cancer patients: A pilot longitudinal study. Breast Cancer: Targets and Therapy, 14, 147–160.
Zenitani, M., Nojiri, T., Hosoda, H., Kimura, T., Tokudome, T., Miura, K., Takabatake, H., Miyazato, M., Kangawa, K., & Okumura, M. (2018). Chemotherapy can promote liver metastasis by enhancing adhesion of circulating tumor cells to liver endothelium via heparanase upregulation. Journal of Surgical Research.